Tag : Pfizer

Latest News

Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

Newsemia
VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the initiation of a Phase 2 trial evaluating ZW25...
Latest News

Obesity linked to increased risk of cardiotoxicity in chemotherapy-treated patients with breast cancer

Newsemia
Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such as trastuzumab. Both types of drugs are major culprits in...
Latest News

Accelerating Medicines Partnership program for Parkinson’s disease launches new data portal

Newsemia
The Accelerating Medicines Partnership program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy...
Gastroenterology

Combination therapy improves survival in patients with hepatocellular carcinoma

Newsemia
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma...
AI/ML

Robots help patients manage chronic illness at home

Newsemia
The Mabu robot, with its small yellow body and friendly expression, serves, literally, as the face of the care management startup Catalia Health. The most...
Latest News

Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Newsemia
BRISBANE, Calif. & NEW YORK–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE) today announced updated results from the...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy